Research programme: autologous natural killer cell therapy - PDL BioPharma
Latest Information Update: 16 Jul 2016
At a glance
- Originator PDL BioPharma
- Mechanism of Action Natural killer cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (IV, Injection)
- 09 Dec 2008 Preclinical trials in Multiple myeloma in USA (IV)